OCTA providing two-for-one imaging and practical valueOCT angiography (OCTA) is a revolutionary new tool that adds value to clinical practice. It provides unique insights about retinal and choroidal vasculature compared with conventional OCT along with the advantages of conventional dye-based techniques, said Philip J. Rosenfeld, MD, PhD, at the 2017 Retina Subspecialty Day meeting.
Tumor-targeted therapy changing game for choroidal melanomaEarly results of a phase Ib/II study investigating light-activated AU-011 (Aura Biosciences) for treatment of small-medium choroidal melanoma show good safety and evidence of efficacy for this novel tumor-targeted therapy.
NLP status after open-globe injury not always permanentManagement of patients with loss of light perception after open-globe injury has historically been to observe or enucleate the eye with the goal of reducing the risk of sympathetic ophthalmia. Existing data, however, support rethinking that paradigm and instead considering surgery for carefully selected patients who have a chance for recovering vision.
Sustained drug-delivery technologies shape promising futureDevelopment of technologies for sustained drug delivery is a topic of great interest among retina specialists considering the number of chronic conditions that are managed with repeated intravitreal injections.
Schepens lecturer traces advent, evolution of ophthalmic trialsClinical trials are an indispensable ordeal that are the gold standard for assessing risks and benefits of treatments, said Frederick L. Ferris III, MD.
Gene therapy benefits for retinal dystrophies persist through trialResults from 3 years of follow-up in the phase III trial investigating treatment with adeno-associated viral vector delivery of human RPE65 (voretigene neparvovec, Spark Therapeutics) show this gene therapy has an acceptable safety profile.
AAO 2017: New solutions, New inspirations, New OrleansThe 2017 meeting of the American Academy of Ophthalmology will convene in New Orleans from Nov. 11 to 14. Go to www.aao.org/annual meeting for the latest updates